Education
About Us
Working with TipRanks
Follow Us
Upstream Bio, Inc. (UPB)
NASDAQ:UPB
UPB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.14 - $29.46
Previous CloseN/A
Volume32.37K
Average Volume (3M)522.76K
Market Cap
$1.01B
Enterprise Value$198.38M
Total Cash (Recent Filing)$393.58M
Total Debt (Recent Filing)$1.56M
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Nov 06, 2025EPS Estimate
-0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.74
Shares Outstanding53,909,428
10 Day Avg. Volume314,183
30 Day Avg. Volume522,757
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.20
Enterprise Value/Revenue72.85
Enterprise Value/Gross Profit72.85
Enterprise Value/Ebitda-1.63
Forecast
1Y Price Target
$75.00Price Target Upside296.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessUpstream Bio's topline phase 2 results for verekitug in CRSwNP showed significant improvements in key secondary endpoints, exceeding expectations.
Investment PotentialThe market contemplates verekitug’s potential as an intriguing biologic option in CRSwNP with these derisking/validating results.
Market InterestUPB shares have outperformed significantly in anticipation of the phase 2 data, reflecting strong market interest.
Bears Say
Clinical Trial CompetitionDespite competition in the anti-TSLP antibody space, verekitug is still the only anti-TSLPR antibody in clinical development.
Operating ExpensesUpstream Bio reported Q2 OpEx of ($45M), above the estimated ($36M).
Upstream Bio, Inc. News
UPB FAQ
What was Upstream Bio, Inc.’s price range in the past 12 months?
Upstream Bio, Inc. lowest stock price was $5.14 and its highest was $29.46 in the past 12 months.
What is Upstream Bio, Inc.’s market cap?
Upstream Bio, Inc.’s market cap is $1.01B.
When is Upstream Bio, Inc.’s upcoming earnings report date?
Upstream Bio, Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 27 days.
How were Upstream Bio, Inc.’s earnings last quarter?
Upstream Bio, Inc. released its earnings results on Aug 06, 2025. The company reported -$0.74 earnings per share for the quarter, missing the consensus estimate of -$0.61 by -$0.13.
Is Upstream Bio, Inc. overvalued?
According to Wall Street analysts Upstream Bio, Inc.’s price is currently Undervalued.
Does Upstream Bio, Inc. pay dividends?
Upstream Bio, Inc. does not currently pay dividends.
What is Upstream Bio, Inc.’s EPS estimate?
Upstream Bio, Inc.’s EPS estimate is -0.76.
How many shares outstanding does Upstream Bio, Inc. have?
Upstream Bio, Inc. has 53,909,428 shares outstanding.
What happened to Upstream Bio, Inc.’s price movement after its last earnings report?
Upstream Bio, Inc. reported an EPS of -$0.74 in its last earnings report, missing expectations of -$0.61. Following the earnings report the stock price went up 7.871%.
Which hedge fund is a major shareholder of Upstream Bio, Inc.?
Currently, no hedge funds are holding shares in UPB
Upstream Bio, Inc. Stock Smart Score
Company Description
Upstream Bio, Inc.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.
UPB Stock 12 Month Forecast
Average Price Target
$75.00
▲(296.41% Upside)
Technical Analysis
Theravance Biopharma
―
Bicycle Therapeutics
―
Prime Medicine, Inc.
―
Bicara Therapeutics Inc.
―
Zenas BioPharma, Inc.
―
Ownership Overview
28.89% Insiders
13.21% Mutual Funds
46.32% Other Institutional Investors
8.19% Public Companies and
Individual Investors